Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 116

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 4
Chunk 116
---
 applications, we filed national phase applications in member states of the PCT including Europe, PRC and
12 other jurisdictions. The claimed inventions are described as: “ Compounds Affecting Pigment Production and Methods for Treatment
of Bacterial Diseases.”

Four (4) US patents, two (2)
PRC patents, two (2) Japanese patents, and two (2) Israeli patents have been granted by various patent offices respectively.

Acticule has the right to
grant sublicenses to third parties under the license agreements without prior approval from Versitech Limited and to assign the agreements
to any successor to the business related to the licenses. In the event that Acticule makes an improvement to the licensed technologies,
so long as the improvement does not incorporate any licensed patents, Acticule will be the owner to such improvement, subject to a non-exclusive
royalty-free license being granted back to Versitech Limited for academic and research purposes only.

The exclusive license agreements
shall be in effect until the expiration of all licensed patents (please refer to the patent expiration dates under “ Item 4. Information
on the Company - B. Business Overview - Intellectual Property”). Acticule may terminate the licenses at any time with
6-month written notice in advance. Either party may terminate the agreements upon a material breach by other party.

SACT-1: A Repurposed Drug for the Treatment
of Neuroblastoma

Drug repurposing is a strategy
for identifying new indications for approved or investigational drugs that are outside the scope of the original medical uses. It is often
viewed as a lower-cost method for drug commercialization, as it is based on already-approved drugs (which has been proven to be safe for
human use by the respective governing regulatory agency) and explores new target indications. (Ashburn, T. T. & Thor, K. B. Drug repositioning:
identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673 - 683, 2004).

One of the advantages of drug
repurposing is a lower development risk due to safety and toxicity, as well as other properties related to water solubility, absorption,
distribution and metabolism, as the safety and CMC profiles of marketed drugs are usually well-established. Due to the same reason, the
development time is also shortened because there is no need to repeat the whole spectrum of the safety assessment. As a result, the drug
repurposing approach appears